Skip to content

Use of Injection Botulinum Toxin for Chronic Nerve Pain in Skin Disorders

Neurotox for Neuroderm: To study the efficacy and safety of Botulinum Toxin in Post-Herpetic Neuralgia and Notalgia Paresthetica - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/05/110860
Enrollment
15
Registered
2026-05-21
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B028- Zoster with other complications

Interventions

Intervention1: Inj Botulinum Toxin-A in Post-Herpetic Neuralgia and Notalgia Paresthetica.: Participants diagnosed with post-herpetic neuralgia (PHN) or notalgia paresthetica (NP) will receive intrade

Sponsors

Krishna Vishwa Vidyapeeth (Deemed to be University)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Postherpetic neuralgia: Persistent dermatomal pain lasting greater than 3 months after the onset of herpes zoster. Notalgia Paresthetica (NP): Localised pruritus or dysesthesia in the thoracic region lasting for greater than 6 months. Visual Analogue Scale (VAS) pain score of greater than 4 at baseline.

Exclusion criteria

Exclusion criteria: 1. Treatment with botulinum toxin in the past 6 months. 2. History of neuromuscular disorders. 3. Coagulopathy or bleeding disorders. 4. Pregnancy or lactation. 5. Presence of active skin infection at the planned injection site. 6. Lesions located on the face or neck. 7. Known allergy or hypersensitivity to botulinum toxin type A (BoNT-A).

Design outcomes

Primary

MeasureTime frame
VAS Score and Dermatology Life Quality index (DLQI)Timepoint: Baseline, 4 weeks, 12 weeks

Secondary

MeasureTime frame
To evaluate patient satisfaction, Adverse event Timepoint: 4weeks, 12 weeks

Countries

India

Contacts

Public ContactDr Varsha Jamale

Krishna Vishwa Vidyapeeth (Deemed to be University),Karad

jamalevarsha@gmail.com9822572887

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026